Skip to main content
. 2015 May 14;36(28):1805–1811. doi: 10.1093/eurheartj/ehv177

Table 1.

Baseline demographic characteristics of the ITT population

Rivaroxaban (N = 124) VKA (N = 124) Total (N = 248) P Value
Mean age, years (SD) 58.6 (9.9) 60.5 (10.5) 59.6 (10.2) 0.211
Age ≥75, n (%) 5 (4.0) 10 (8.1) 15 (6.0) 0.183
Age 65–75 34 (27.4) 41 (33.1) 75 (30.2) 0.183
Male 86 (69.4) 90 (72.6) 176 (71.0) 0.576
Caucasian 112 (90.3) 116 (93.5) 228 (91.9) 0.351
Non-Hispanic/Latino 90 (72.6) 94 (75.8) 184 (74.2) 0.562
Paroxysmal AF 95 (76.6) 87 (70.2) 182 (73.4) 0.250
Prior cardioversion 47 (37.9) 54 (43.5) 101 (40.7) 0.366
Prior catheter ablation 11 (8.9) 11 (8.9 22 (8.9) 0.563
Mean BMI, kg/m2 (SD) 29.8 (5.7) 28.9 (5.5) 29.4 (5.6) 0.231
CHF 12 (9.7) 9 (7.3) 21 (8.5) 0.494
Hypertension 59 (47.6) 57 (46.0) 116 (46.8) 0.799
Mean systolic BP, mmHg (SD) 133 (16) 131 (18) 132 (17) 0.325
Mean diastolic BP, mmHg (SD) 81 (10) 79 (11) 80 (10) 0.233
Diabetes mellitus 8 (6.5) 14 (11.3) 22 (8.9) 0.180
Prior Stroke/TIA/embolism 0 3 (2.4) 3 (1.2) 0.081
Vascular disease 22 (17.7) 25 (20.2) 47 (19.0) 0.627
Mean CHADS2 Score (SD) 0.7 (0.7) 0.8 (0.9) 0.7 (0.8) 0.179
Mean CHA2DS2-VASc Score (SD) 1.5 (1.3) 1.7 (1.4) 1.6 (1.3) 0.277
Beta blocker, selective 65 (52.4) 61 (49.2) 126 (50.8) 0.611
Antiarrhythmic, class IC 51 (41.1) 49 (39.5) 100 (40.3) 0.796
Antiarrhythmic, class III 30 (24.2) 39 (31.5) 69 (27.8) 0.202
Vitamin K antagonist 36 (29.0) 37 (29.8) 73 (29.4) 0.889
Rivaroxaban 23 (18.5) 29 (23.4) 52 (21.0) 0.349
Dabigatran 12 (9.7) 10 (8.1) 22 (8.9) 0.655
Antiplatelet agent 37 (29.8) 29 (23.4) 66 (26.6) 0.250
Proton pump inhibitor 26 (21.0) 18 (14.5) 44 (17.7) 0.184

Units are listed as n(%) unless otherwise indicated.

BMI, body mass index; BP, blood pressure; CHF, congestive heart failure; ITT, intention-to treat; SD, standard deviation.